Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers

Orna Diav-Citrin, Svetlana Shechtman, Yehudit Halberstadt, Victoriya Finkel-Pekarsky, Rebecka Wajnberg, Judy Arnon, Elena Di Gianantonio, Maurizio Clementi, Asher Ornoy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Abstract

Objective: To examine first trimester safety of angiotensin-converting-enzyme-inhibitors (ACEIs) or angiotensin-receptor-blockers (ARBs). Study design: Prospective observational cohort regarding pregnancy ACEI/ARBs-exposure including contacts to two Teratology Information Services in Israel (1994-2007) and Italy (1990-2008), with two comparison groups: (1) exposed to other antihypertensives (OAH) (2) after non-teratogenic exposure (NTE) in similar time frames. Results: 252 ACEI/ARBs-exposed, 256 OAH-exposed and 495 NTE-exposed pregnancies were followed-up. The rate of major congenital anomalies was comparable between the groups (8/190, 4.2%, ACEI/ARB; 9/212, 4.2%, OAH; 18/471, 3.8% NTE; p= 0.954) among first trimester exposed pregnancies. The median gestational age at delivery was two weeks earlier, rate of preterm deliveries more than 2-fold higher, and median birth weight more than 200 g lower in the ACEI/ARB and OAH groups compared to the NTE group. Conclusion: The present study suggests that ACEI/ARBs are not major teratogens when used in the first trimester, and can reassure women with similar exposures.

Original languageEnglish
Pages (from-to)540-545
Number of pages6
JournalReproductive Toxicology
Volume31
Issue number4
DOIs
StatePublished - May 2011

Keywords

  • Angiotensin converting enzyme inhibitors
  • Angiotensin receptor blockers
  • Congenital anomalies
  • Pregnancy

Fingerprint

Dive into the research topics of 'Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers'. Together they form a unique fingerprint.

Cite this